Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Diamedica Therapeutics Inc (DMAC)

Diamedica Therapeutics Inc (DMAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 449,424
  • Shares Outstanding, K 52,077
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,440 K
  • EBIT $ -34 M
  • EBITDA $ -35 M
  • 60-Month Beta 1.31
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.52

Options Overview Details

View History
  • Implied Volatility 169.97% (-27.04%)
  • Historical Volatility 86.76%
  • IV Percentile 59%
  • IV Rank 17.38%
  • IV High 670.92% on 04/04/25
  • IV Low 64.61% on 03/24/25
  • Expected Move (DTE 14) 0.11 (1.26%)
  • Put/Call Vol Ratio 0.19
  • Today's Volume 177
  • Volume Avg (30-Day) 118
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 4,169
  • Open Int (30-Day) 3,880
  • Expected Range 8.67 to 8.89

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.17
  • Number of Estimates 1
  • High Estimate -0.17
  • Low Estimate -0.17
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +5.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.26 +66.92%
on 11/13/25
9.23 -4.88%
on 11/26/25
+2.13 (+32.03%)
since 11/05/25
3-Month
5.26 +66.92%
on 11/13/25
9.23 -4.88%
on 11/26/25
+2.64 (+43.00%)
since 09/05/25
52-Week
3.19 +175.24%
on 04/07/25
9.23 -4.88%
on 11/26/25
+3.41 (+63.50%)
since 12/05/24

Most Recent Stories

More News
3 Biotech Stocks Wall Street Analysts Predict Will More Than Double

What makes analysts so bullish about these three names from the sector?

MEHCQ : 3.5000 (-2.78%)
GHRS : 14.89 (-3.00%)
TYRA : 21.50 (-2.76%)
DMAC : 8.78 (+1.74%)
XBI : 123.41 (+0.13%)
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Preeclampsia Phase 2 IST Trial: Part 1a Dose Escalation Cohort Complete with Expansion Cohort Now Enrolling; Screening for Part 3, Fetal Growth Restriction Cohort, Expected to Start in Coming Weeks ...

DMAC : 8.78 (+1.74%)
DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today...

DMAC : 8.78 (+1.74%)
DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its third...

DMAC : 8.78 (+1.74%)
Why Wall Street Experts Believe This Biotech Stock Represents a Major Opportunity

Following a bullish initiation report by TD Cowen, DiaMedica Therapeutics (DMAC) is trading higher as analysts express high conviction in its breakthrough drug candidate, DM199, which showed

DMAC : 8.78 (+1.74%)
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today...

DMAC : 8.78 (+1.74%)
This Hidden Gem Biotech is the Only Small-Cap Among Billionaire Investor Leon Cooperman's Top Market-Beating Picks

DiaMedica Therapeutics stands out in Leon Cooperman's portfolio as his only small-cap and only biotech stock, which, along with a strong year-to-date return, signals his confidence in its pot

COOP : 210.79 (-2.77%)
MIR : 25.02 (-1.88%)
DMAC : 8.78 (+1.74%)
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, today...

DMAC : 8.78 (+1.74%)
DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today...

DMAC : 8.78 (+1.74%)
DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Positive Phase 2 Interim Data Evaluating DM199 in Preeclampsia Showed Statistically Significant Reductions in Blood Pressure and Pulsatility...

DMAC : 8.78 (+1.74%)

Business Summary

DiaMedica Therapeutics Inc. is a biopharmaceutical company. It engages in the development of novel recombinant proteins and monoclonal antibodies. The companys lead product principally consists DM199, a recombinant human tissue kallikrein-1 protein. It operates primarily in the United States and Canada....

See More

Key Turning Points

3rd Resistance Point 9.30
2nd Resistance Point 9.13
1st Resistance Point 8.96
Last Price 8.78
1st Support Level 8.61
2nd Support Level 8.44
3rd Support Level 8.26

See More

52-Week High 9.23
Last Price 8.78
Fibonacci 61.8% 6.92
Fibonacci 50% 6.21
Fibonacci 38.2% 5.50
52-Week Low 3.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar